William A. Haseltine, Contributor

This is the third in our series that outlines what we know about Omicron. We summarize the finding of recent experiments by Cameroni et al. in a bioRxiv preprint from December 14th.

A recent study has found that blood transfusions from highly active mice into sedentary mice boosted brain function in the sedentary recipients. This discovery may mark a significant step in uncovering treatments to slow the progression of neurodegener…

Results of a preliminary study show that we may be one step closer to achieving a cure for Type 1 diabetes.

This is the second of a two-part series. In part one, we described the mutations in the Omicron Spike protein. In part two, we will describe mutations in other parts of the genome.

Immunocompromised Americans who are not adequately protected by their Covid-19 vaccination series will now have an additional option for long-term protection in the form of an antibody cocktail drug developed by AstraZeneca.

Omicron is sending a message, loud and clear: this virus is capable of far more changes and far more variation than most ever thought possible and it will keep coming back to haunt us again and again.

A new variant, Omicron, very effectively evades the neutralizing antibodies of the Pfizer vaccine regimen, according to a recent study. Here we describe the mutations in the Omicron Spike protein.

Researchers provide valuable new insights into potential mechanisms underlying Covid-19 neurological symptoms.

Here we detail three possible origins of the new variant of concern: Omicron.